home / stock / smmt / smmt news

SMMT News and Press, Summit Therapeutics Inc. From 05/30/24

Stock Information
Company Name: Summit Therapeutics Inc.
Stock Symbol: SMMT
Market: NASDAQ
Menu
SMMT SMMT Quote SMMT Short SMMT News SMMT Articles SMMT Message Board
Get SMMT Alerts

News, Short Squeeze, Breakout and More Instantly...
SMMT - US Companies Moving the Markets, Evening edition
Thu, May 30, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 27.3% to $0.5653 on volume of 583,041,328 shares Cue Health Inc. (HLTH) rose 32.3% to $0.0725 on volume of 576,400,871 shares Greenwave Technology Solutions Inc. (GWAV) fell 15.0% t...
SMMT - 24/7 Market News- Summit Therapeutics Reported Positive Phase III Clinical Trial Data

2024-05-30 15:34:05 ET DENVER, Colo., May 30, 2024 ( 247marketnews.com )- Summit Therapeutics Inc. (NASDAQ: SMMT ) reported that the HARMONi-2, or AK112-303, Phase III clinical trial met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonesc...

SMMT - Summit lead asset beats Merck's Keytruda in a first in lung cancer

2024-05-30 15:12:02 ET More on Summit Therapeutics Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript Summit ...

SMMT - Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China

Unprecedented: Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized Phase III Clinical Trial in NSCLC Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Trial Conducted by Akeso PFS Improvement Was Obs...
SMMT - US Companies Moving the Markets, Evening edition
Tue, May 28, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 46.0% to $0.2601 on volume of 655,453,952 shares Sharps Technology Inc. (STSS) rose 141.4% to $0.5174 on volume of 299,690,189 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.4% to $0.0786 on...

SMMT - INSM, SINT and POAI are among mid-day movers

2024-05-28 14:04:21 ET More on Mid-day movers & stock Semler Scientific: Great Product Can Still Thrive Post Medicare Advantage Semler Scientific, Inc. (SMLR) Q1 2024 Earnings Call Transcript G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript A...

SMMT - Why Summit Therapeutics Stock Is Sinking Today

2024-05-28 12:13:41 ET Shares of Summit Therapeutics (NASDAQ: SMMT) were sinking 22.6% as of 11:10 a.m. ET on Tuesday. This sell-off follows a similar steep decline of 22% on Friday after Summit revealed late-stage data for its lead candidate, ivonescimab, in combination with chemot...
SMMT - LIDR, HOOK and BCAB among mid-day movers

2024-05-24 12:58:09 ET More on BioAtla, HOOKIPA Pharma, etc. BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript AEye, Inc. (LIDR) Q1 2024 Earnings Call Transcript BioAtla: A Buried ADC Concern Gets Some New Life In 2024 AEye Q1 2024 Earnings Preview ...

SMMT - AIMD, BCG and RENB among pre-market losers

2024-05-24 08:16:00 ET More on pre-market losers & stocks. RenovaroCube to acquire 100% ownership of Cyclomics Financial information for Ainos Financial information for Binah Capital Group, Inc. Financial information for Renovaro Inc. Compare metr...

SMMT - Summit Therapeutics falls after late-stage data for lead asset

2024-05-24 07:45:37 ET More on Akeso, Summit Therapeutics, etc. Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript ...
Previous 10 Next 10